Vanda Pharmaceuticals (VNDA) Non-Current Deferred Tax Liability (2014 - 2017)

Vanda Pharmaceuticals has disclosed Non-Current Deferred Tax Liability across 4 years of filings, most recently posting -$386000.0 for Q4 2017.

• Non-Current Deferred Tax Liability for Q4 2017 came in at -$386000.0, down 157.96% year-over-year; the trailing twelve-month figure through Dec 2017 was -$386000.0 (down 157.96% YoY), and the FY2017 annual result was -$386000.0, down 157.96% from the prior year.
• Non-Current Deferred Tax Liability came in at -$386000.0 for Q4 2017 at Vanda Pharmaceuticals, down from $666000.0 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.1 million in Q4 2015 to a low of -$386000.0 in Q4 2017.
• The 4-year median for Non-Current Deferred Tax Liability is $336000.0 (2014), against an average of $346500.0.
• Across the five-year window, Non-Current Deferred Tax Liability surged 18233.33% in 2015 and slumped 157.96% in 2017, its largest moves.
• Vanda Pharmaceuticals' Non-Current Deferred Tax Liability stood at $6000.0 in 2014, then soared by 18233.33% to $1.1 million in 2015, then plunged by 39.45% to $666000.0 in 2016, then tumbled by 157.96% to -$386000.0 in 2017.
• The last three Non-Current Deferred Tax Liability figures came in at -$386000.0 (Q4 2017), $666000.0 (Q4 2016), and $1.1 million (Q4 2015), per Business Quant data.